Inc.: How GLP-1 Medications Are Changing Fast-Food Habits

Inc. recently featured insights from Sean Arora, MD, CEO and Co-Founder of Arora Health, on how GLP-1 medications are changing consumer eating habits and influencing the strategies of major restaurant chains like McDonald's.

As GLP-1 medications become more widely used for weight management, their effects are extending beyond healthcare and into the food industry. In the article, "The CEO of McDonald's Says an Unlikely Group Is Turning to Happy Meals. Now the Chain Is Rethinking Its Strategy," Dr. Arora explains how appetite suppression and earlier satiety are influencing portion preferences, while emphasizing the importance of maintaining balanced nutrition during treatment.

Article highlights

The Inc. feature explores several key themes, including:

• Recognizing the impact of GLP-1 medications on eating habits. GLP-1 medications can reduce appetite and increase feelings of fullness, leading patients to consume smaller portions and reconsider their usual food choices.
• Understanding the shift toward smaller meals. As patients adjust to eating less, smaller menu options, including McDonald's Happy Meals, may become more appealing to adults who previously preferred larger portions.
• Adapting restaurant strategies to changing consumer behavior. Major restaurant chains are beginning to explore smaller portions and lighter menu options as GLP-1 adoption influences customer preferences and purchasing decisions.
• Maintaining nutritional quality during weight loss. Eating smaller portions does not necessarily mean meeting nutritional needs. Patients taking GLP-1 medications should continue prioritizing adequate protein, fiber, and essential nutrients.
• Balancing convenience with healthy eating habits. Familiar fast-food options may still fit into a patient's routine, but portion control should be considered alongside overall dietary quality and long-term health goals.

How GLP-1 medications are reshaping consumer behavior

Dr. Arora shares a firsthand observation of how significantly GLP-1 medications can change patients' appetites:

"I have patients telling me they used to demolish two Big Macs and now genuinely can’t finish one cheeseburger."

While smaller portions may better align with reduced appetites, Dr. Arora also cautions against assuming that a smaller meal automatically provides balanced nutrition. Patients still need adequate protein, fiber, and other essential nutrients to support their health throughout treatment.

The growing adoption of GLP-1 medications is creating changes that extend well beyond weight management. For restaurants and food brands, these shifts present opportunities to rethink portion sizes and menu offerings. For healthcare providers, they reinforce the importance of helping patients develop sustainable eating habits that support their nutritional needs and long-term health.

Read "The CEO of McDonald's Says an Unlikely Group Is Turning to Happy Meals. Now the Chain Is Rethinking Its Strategy" in Inc.

‍